Buyout + growth fund research profile
KKR operates in India through private equity, infrastructure, climate and credit, with a local team that combines global sector playbooks and India deal execution. Its private-equity lens has covered financial services, healthcare, consumer and technology-enabled businesses.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
KKR (India) uses a buyout + growth approach across Health, consumer, fin services, infra.
Current evidence
KKR’s February 2026 India update describes active deployment and monetization opportunities across private equity, infrastructure, climate and credit; its current portfolio records named India positions including Max Healthcare, JB Chemicals, Vini Cosmetics, Lighthouse Learning, Reliance Retail and Advanta Seeds.
Strategy
Buyout + growth
Sector focus
Health, consumer, fin services, infra
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
KKR’s February 2026 India update describes active deployment and monetization opportunities across private equity, infrastructure, climate and credit; its current portfolio records named India positions including Max Healthcare, JB Chemicals, Vini Cosmetics, Lighthouse Learning, Reliance Retail and Advanta Seeds.
Investor questions
KKR (India) is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout + growth, with a sector focus of Health, consumer, fin services, infra. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to KKR (India) in the reviewed public sources: Max Healthcare, JB Chemicals, Vini Cosmetics, Lighthouse Learning, Reliance Retail, Advanta Seeds. It does not represent a complete current portfolio unless the manager has published one.
KKR’s disclosed India record includes exits such as Alliance Tire and Gland Pharma and scaled positions including Jio Platforms, Max Healthcare, JB Chemicals and InCred. Public sources do not provide a consolidated India fund IRR or DPI figure. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: KKR describes more than $10B invested in India private equity since 2006 in public reporting, while its global private-equity platform reports $207B capital invested as of June 30, 2026; India PE vehicle size is not separately disclosed.. Public terms or access information: Buyout, growth and core private equity sit alongside India infrastructure, climate and credit. India cheque sizes, concentration limits and reserve policy are not consistently disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Gaurav Trehan, Akshay Tanna, Hardik Shah. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Current India deal-team composition and India-only allocation within KKR’s global PE, infrastructure and credit platform require periodic re-verification..
2026: KKR’s February 2026 India update describes active deployment and monetization opportunities across private equity, infrastructure, climate and credit; its current portfolio records named India positions including Max Healthcare, JB Chemicals, Vini Cosmetics, Lighthouse Learning, Reliance Retail and Advanta Seeds.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.